These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12778985)

  • 1. ALLHAT. Is it all hat?
    Glancy DL
    J La State Med Soc; 2003; 155(2):68-70. PubMed ID: 12778985
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
    Yamal JM; Oparil S; Davis BR; Alderman MH; Calhoun DA; Cushman WC; Fendley HF; Franklin SS; Habib GB; Pressel SL; Probstfield JL; Sastrasinh S;
    J Am Soc Hypertens; 2014 Nov; 8(11):808-19. PubMed ID: 25455006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Consequences of ALLHAT: Thiazides rehabilitated--time to change prescription patterns].
    Hernborg A; Håkansson J; Werkö L; Berglund G
    Lakartidningen; 2003 Feb; 100(6):408-10. PubMed ID: 12607432
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Muntner P; Levitan EB; Lynch AI; Simpson LM; Whittle J; Davis BR; Kostis JB; Whelton PK; Oparil S
    J Clin Hypertens (Greenwich); 2014 May; 16(5):323-30. PubMed ID: 24739073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Papademetriou V; Piller LB; Ford CE; Gordon D; Hartney TJ; Geraci TS; Reisin E; Sumner BM; Wong ND; Nwachuku C; Narayan P; Haywood J; Habib G;
    J Clin Hypertens (Greenwich); 2003; 5(6):377-84. PubMed ID: 14688492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omission of drug dose information.
    Hollenberg NK
    Arch Intern Med; 2006 Feb; 166(3):368; author reply 368-9. PubMed ID: 16476880
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
    Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Dhruva SS; Huang C; Spatz ES; Coppi AC; Warner F; Li SX; Lin H; Xu X; Furberg CD; Davis BR; Pressel SL; Coifman RR; Krumholz HM
    Hypertension; 2017 Jul; 70(1):94-102. PubMed ID: 28559399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
    Lynch AI; Eckfeldt JH; Davis BR; Ford CE; Boerwinkle E; Leiendecker-Foster C; Arnett DK
    Pharmacogenet Genomics; 2012 May; 22(5):355-66. PubMed ID: 22388798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ALLHAT: Old Hat Hits All? On selection of the optimal antihypertensive drug].
    Slany J
    Wien Klin Wochenschr; 2003 Mar; 115(5-6):149-51. PubMed ID: 12741071
    [No Abstract]   [Full Text] [Related]  

  • 18. Diuretics: drugs of choice for the initial management of patients with hypertension.
    Fuchs FD
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):35-41. PubMed ID: 15030295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A family physician questions the conclusions from ALLHAT.
    Standridge JB
    Am J Hypertens; 2004 Apr; 17(4):361-5. PubMed ID: 15062891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice].
    Faulhaber HD
    MMW Fortschr Med; 2001 May; 143(22):30-2. PubMed ID: 11460395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.